Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.
Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.
复制标题
DOI：
10.1016/j.dadr.2023.100213
复制
发表时间：
2024-03
期刊：
影响因子：
--
通讯作者：
Glick, S N
中科院分区：
文献类型：
--
作者：
Tsui, J I;Gojic, A J;Pierce, K A;Tung, E L;Connolly, N C;Radick, A C;Hunt, R R;Sandvold, R;Taber, K;Ninburg, M;Kubiniec, R H;Scott, J D;Hansen, R N;Stekler, J D;Austin, E J;Williams, E C;Glick, S N
一个合作的，药剂师领导的模型在吸毒者中治疗丙型肝炎（PWID）。超过一半的人开始服用丙型肝炎药物;大多数完成药物/实验室检查的人显示治愈。患者对药剂师护理的满意度很高，一些HIV危险行为得到改善。注射吸毒者（PWID）是直接作用抗病毒药物（DAA）治疗以消除丙型肝炎病毒（HCV）的关键人群。我们开发了一个药剂师，医生和患者导航协作护理模式（PPP-CCM）提供的HCV治疗，这项研究描述了与HCV治疗（初始评估，治疗开始，完成和治愈）的临床结果，以及患者的满意度。我们对患有HCV的成人PWID进行了一项单臂前瞻性初步研究。参与者完成了基线和6个月的随访调查，治疗和结果从电子健康记录中提取。主要结局是与药剂师进行HCV评价的联系;次要结局包括DAA开始、完成和治愈，以及患者报告的满意度。在入组的40名PWID中，平均年龄为43.6岁，12名（30%）为女性，20名（50%）为非白人，15名（38%）为无家可归者。38例（95%）成功联系到药剂师进行初步评价。其中，21/38例（55%）开始DAA，16/21例（76%）完成治疗。在完成治疗的那些具有病毒载量数据以记录他们是否实现“持续病毒学应答”（即治愈）的患者中，发现10/11（91%）被治愈。有很高的满意度与100%的回答“同意或强烈同意”，他们有一个积极的经验与药剂师。几乎所有参与该试点的参与者都成功地与药剂师联系起来进行评估，超过一半的参与者开始使用DAA;结果为药剂师主导的HCV治疗PWID模型的可行性提供了初步证据。NCT 04698629。
A collaborative, pharmacist-led model treated hep C among people who use drugs (PWID). Over half started hep C meds; majority of those who completed meds/labs showed cure. Patient satisfaction for pharmacist-care was high and some HIV risk behaviors improved. People who inject drugs (PWID) are a key population for treatment with direct-acting antiviral medications (DAAs) to eliminate hepatitis C virus (HCV). We developed a Pharmacist, Physician, and Patient Navigator Collaborative Care Model (PPP-CCM) for delivery of HCV treatment; this study describes clinical outcomes related to HCV treatment (initial evaluation, treatment initiation, completion, and cure), as well as patient satisfaction. We conducted a single-arm prospective pilot study of adult PWID living with HCV. Participants completed baseline and six-month follow-up surveys, and treatment and outcomes were abstracted from electronic health records. Primary outcome was linkage to pharmacist for HCV evaluation; secondary outcomes included DAA initiation, completion, and cure, as well as patient-reported satisfaction. Of the 40 PWID enrolled, mean age was 43.6 years, 12 (30 %) were female, 20 (50 %) were non-white, and 15 (38 %) were unhoused. Thirty-eight (95 %) were successfully linked to the pharmacist for initial evaluation. Of those, 21/38 (55 %) initiated DAAs, and 16/21 (76 %) completed treatment. Among those completing treatment who had viral load data to document whether they achieved “sustained virologic response", i.e. cure, 10/11 (91 %) were found to be cured. There was high satisfaction with 100 % responding “agree or strongly agree” that they had a positive experience with the pharmacist. Nearly all participants in this pilot were successfully linked to the pharmacist for evaluation, and more than half were started on DAAs; results provide preliminary evidence of feasibility of pharmacist-led models of HCV treatment for PWID. NCT04698629.
影响因子：
2.1
作者：
Pollini, Robin A.;Slocum, Susannah;Ozga, Jenny E.;Joyce, Rebecca;Xuan, Ziming;Green, Traci C.;Walley, Alexander Y.
通讯作者：
Walley, Alexander Y.